Suppr超能文献

在开伯尔-普赫图赫瓦省(KPK)的慢性 HCV 患者中,标准干扰素治疗的应答率。

Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).

机构信息

Centre for Biotechnology and Microbiology, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan.

出版信息

Virol J. 2012 Jan 14;9:18. doi: 10.1186/1743-422X-9-18.

Abstract

BACKGROUND

Interferon based therapy is used to eradicate the Hepatitis C Virus from the bodies of the infected individuals. HCV is highly prevalent in Khyber Pakhtunkhwa (KPK) that is why it is important to determine the response of standard interferon based therapy in Chronic HCV patients of the region.

STUDY DESIGN

A total of 174 patients were selected for interferon based therapy. The patients were selected from four different regions of KPK. After confirmation of active HCV infection by Real Time PCR, standard interferon with ribavirn was given to patients for 6 months. After completion of therapy, end of treatment virologic response (ETR) was calculated.

RESULTS

Out of total 174 patients, 130 (74.71%) showed ETR and 44 (25.28%) did not show ETR. In district Bunir, out of 52 patients, 36 (69.23%) showed ETR and 16 (30.79%) did not show ETR. In district Mardan, out of the total 74 patients, 66 (89.18%) were negative for HCV RNA and 8 (10.81%) were resistant to therapy. In Peshawar, out of 22, 16 (60%) were negative and 6 (40%) were positive for HCV RNA at the end of 6 months therapy. In the Federally Administered Tribal Area (FATA), out of 18 only 10 (55.5%) were negative and 8 (44.45%) were positive for active HCV infection.

CONCLUSION

It is concluded that the response of antiviral therapy against HCV infection in chronic HCV patients of KPK province is 74.71%. The high response rate may be due to the prevalence of IFN-responsive HCV genotypes (2 and 3) in KPK.

摘要

背景

基于干扰素的治疗用于清除感染个体体内的丙型肝炎病毒。在开伯尔-普赫图赫瓦省(开普省),丙型肝炎病毒的流行率很高,因此确定该地区慢性丙型肝炎患者对标准干扰素治疗的反应非常重要。

研究设计

共选择了 174 名患者接受基于干扰素的治疗。这些患者来自开普省的四个不同地区。在通过实时 PCR 确认丙型肝炎病毒的活性感染后,给予患者标准干扰素联合利巴韦林治疗 6 个月。完成治疗后,计算治疗结束时的病毒学应答(ETR)。

结果

在总共 174 名患者中,有 130 名(74.71%)显示 ETR,44 名(25.28%)未显示 ETR。在本尼尔区,52 名患者中,36 名(69.23%)显示 ETR,16 名(30.79%)未显示 ETR。在马尔丹区,74 名患者中,66 名(89.18%)对 HCV RNA 呈阴性,8 名(10.81%)对治疗耐药。在白沙瓦,22 名患者中有 16 名(60%)在 6 个月治疗结束时 HCV RNA 阴性,6 名(40%)阳性。在联邦直辖部落地区(FATA),只有 18 名患者中的 10 名(55.5%)对 HCV 感染呈阴性,8 名(44.45%)呈阳性。

结论

开普省慢性丙型肝炎患者抗病毒治疗对 HCV 感染的反应率为 74.71%。高反应率可能是由于开普省 IFN 反应性 HCV 基因型(2 和 3)的流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1610/3284448/51453222e2cc/1743-422X-9-18-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验